Profile: Trellis Bioscience
BioHealth Investor Company Directory Profile
TRELLIS BIOSCIENCE
2-B Corporate Drive
South San Francisco, CA 94080
Phone: 650.616.1100
Fax: 650.589.4860
The next 21st century breakthrough in monoclonal antibody technology is currently housed at Trellis Bioscience. This South San Francisco company has developed a breakthrough technology platform for cellular informatics. Trellis uses nanotechnology, software and digital microscopy to better locate and recover the original rare favorable cells which will be used to make monoclonal antibodies.
The technology has broad applications in the discovery and production of therapeutic monoclonal antibodies. The Trellis proprietary technology, including patents and know-how, uses nanoparticles in a live cell environment to achieve multiplexing and miniaturization in one step. This capability addresses key bottlenecks in the research and discovery process as well as production, such as:
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
TRELLIS BIOSCIENCE2-B Corporate Drive
South San Francisco, CA 94080
Phone: 650.616.1100
Fax: 650.589.4860
The next 21st century breakthrough in monoclonal antibody technology is currently housed at Trellis Bioscience. This South San Francisco company has developed a breakthrough technology platform for cellular informatics. Trellis uses nanotechnology, software and digital microscopy to better locate and recover the original rare favorable cells which will be used to make monoclonal antibodies.
The technology has broad applications in the discovery and production of therapeutic monoclonal antibodies. The Trellis proprietary technology, including patents and know-how, uses nanoparticles in a live cell environment to achieve multiplexing and miniaturization in one step. This capability addresses key bottlenecks in the research and discovery process as well as production, such as:
Elimination of time and resource-intensive cloning and propagation prior to specificity and affinity analysis, and rapid confirmation of clonality after subcloning
Epitope mapping in a comprehensive, efficient manner to assure targeting of the optimal antigen site
Resurrection of failed projects through capture of more favorable, but extremely rare specificities
Selection of high secreting cell populations during manufacturing and scale-up
Characterization and isolation of antibodies from non-transformed populations, making it possible to find rare, highly specific human monoclonal antibodies in a mixed population of human cells from patients and immune donors
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
posted by Nico at
12:49 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home